Investigators at the University of Texas have synthesized new mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) and Bruton tyrosine kinase (BTK) dual-target inhibitors reported to be useful for the treatment of cancer, autoimmune and inflammatory disorders.